RESUMO
We investigate the influence of the autoionizing 3s3p(6)nâ resonances on the fifth harmonic generated by 200-240 nm laser fields interacting with Ar. To determine the influence of a multielectron response we develop the capability within time-dependent R-matrix theory to determine the harmonic spectra generated. The fifth harmonic is affected by interference between the response of a 3s electron and the response of a 3p electron, as demonstrated by the asymmetric profiles in the harmonic yields as functions of wavelength.
RESUMO
We use the time-dependent R-matrix approach to investigate an ultrashort pump-probe scheme to observe collective electron dynamics in C+. The ionization probability of a coherent superposition of the 2s2p;{2} 2D and 2S states shows rapid modulation due to collective dynamics of the two equivalent 2p electrons, with the modulation frequency linked to the dielectronic repulsion. The best insight into this collective dynamics is achieved by a transformation from LS symmetry to the uncoupled basis. Such dynamics may be important in high-harmonic generation using open-shell atoms and ions.
RESUMO
An attosecond pump-probe scheme that combines the use of a free-electron laser pulse with an ultrashort pulse is applied in order to explore the ultrafast excitation dynamics in Ne. We describe the multielectron dynamics using a new nonperturbative time-dependent R-matrix theory. This theory enables the interaction of ultrashort light fields with multielectron atoms and atomic ions to be determined from first principles. By probing the emission of an inner 2s electron from Ne we are also able to study the bound state population dynamics during the free-electron laser pulse.
RESUMO
BACKGROUND: Patients with low Body Mass Index (BMI) on maintenance hemodialysis have a higher mortality risk than patients with elevated BMI. We investigated the use of kinetic modeling to test different hypotheses which have been advanced to explain this relationship. METHODS: Equations from a three-pool urea-kinetic mathematical model (hepatic mass, extracellular fluid, muscle mass and adipose tissue) were solved to yield predictive profiles of solute and putative toxin concentrations versus time for patients of different body weights. RESULTS: For the interdialytic interval, our mathematic model suggests that extracellular solute/toxin concentration increases more rapidly in small patients. Additionally, time average concentration (TAC) is higher for this cohort. A lower value of the muscle mass and adipose tissue mass-transfer coefficient (K(MMAT)), which determines the rate of solute release into the extracellular fluid, exacerbates this difference. CONCLUSION: These results suggest that higher mortality for smaller dialysis patients may be mediated by higher time average toxin concentration, especially for solutes with a low mass-transfer coefficient value.
Assuntos
Índice de Massa Corporal , Doenças Cardiovasculares/mortalidade , Simulação por Computador , Diálise Renal , Humanos , Cinética , Modelos TeóricosRESUMO
Islet-like cell clusters (ILCCs) were derived from murine embryonic stem cells using a slightly modified version of the protocol originally described by Lumelsky et al. in 2001. Analysis with enzyme-linked immunosorbent assays (ELISAs) that distinguish human from murine insulin demonstrated that insulin released from these ILCCs, upon initial in vitro glucose challenge, was of non-murine origin and in fact corresponded to the species of insulin, human or bovine, that had been added to the culture media used to derive ILCCs. This finding convincingly supports the hypothesis that ILCCs are not synthesizing insulin de novo, but rather simply regurgitating insulin taken up during tissue culture. In further experiments, ILCCs were derived in media in which insulin had been replaced by IGF-I with which it shares a common signaling pathway. These ILCCs failed to release any detectable insulin. In contrast, ILCCs produced by various protocols stained positive (dithizone and immunoselective antibodies) for intracellular insulin and, in some cases, C-peptide. Despite the presence of at least some level of de novo, synthesized insulin in ILCCs, the majority of insulin released by ILCCs was sequestered from the exogenous medium.
Assuntos
Embrião de Mamíferos/metabolismo , Insulina/metabolismo , Ilhotas Pancreáticas/metabolismo , Células-Tronco/metabolismo , Animais , Bovinos , Diferenciação Celular , Células Cultivadas , Reações Cruzadas , Embrião de Mamíferos/citologia , Ensaio de Imunoadsorção Enzimática , Transportador de Glucose Tipo 2/metabolismo , Humanos , Insulina/imunologia , Secreção de Insulina , Fator de Crescimento Insulin-Like I/farmacologia , Ilhotas Pancreáticas/citologia , Camundongos , Ratos , Especificidade da Espécie , Células-Tronco/citologiaRESUMO
This report draws upon data from a variety of sources to estimate the size, scope, and growth rate of the contemporary tissue engineering enterprise. At the beginning of 2001, tissue engineering research and development was being pursued by 3,300 scientists and support staff in more than 70 startup companies or business units with a combined annual expenditure of over $600 million. Spending by tissue engineering firms has been growing at a compound annual rate of 16%, and the aggregate investment since 1990 now exceeds $3.5 billion. At the beginning of 2001, the net capital value of the 16 publicly traded tissue engineering startups had reached $2.6 billion. Firms focusing on structural applications (skin, cartilage, bone, cardiac prosthesis, and the like) comprise the fastest growing segment. In contrast, efforts in biohybrid organs and other metabolic applications have contracted over the past few years. The number of companies involved in stem cells and regenerative medicine is rapidly increasing, and this area represents the most likely nidus of future growth for tissue engineering. A notable recent trend has been the emergence of a strong commercial activity in tissue engineering outside the United States, with at least 16 European or Australian companies (22% of total) now active.
Assuntos
Engenharia Tecidual/tendências , Órgãos Artificiais/economia , Órgãos Artificiais/estatística & dados numéricos , Órgãos Artificiais/tendências , Austrália , Transplante de Células/economia , Transplante de Células/estatística & dados numéricos , Europa (Continente) , Indústrias/economia , Indústrias/estatística & dados numéricos , Indústrias/tendências , Engenharia Tecidual/economia , Engenharia Tecidual/estatística & dados numéricos , Transplante de Tecidos/economia , Transplante de Tecidos/estatística & dados numéricos , Transplante de Tecidos/tendências , Estados UnidosRESUMO
This analysis draws upon a variety of sources to provide a tally of the number of patients receiving organ replacement therapies and the costs associated with the provision of such therapies. Constituent data were available from treatment-specific patient registries, peer reviewed reports in scientific literature, business publications, and industry sources. The magnitude and economic scope of the contemporary organ replacement enterprise were found to be much larger than is generally recognized. In the year 2000, the lives of over 20 million patients will be sustained, supported, or significantly improved by functional organ replacement. The impacted population grows at over 10% per year. Worldwide, first year and follow-up costs of organ prosthesis exceeds $300 billion US dollars per year and represents between 7 and 8% of total worldwide health care spending. Remarkably, in the United States, the costs of therapies enabled by organ replacement technology exceed 1% of the Gross Domestic Product. These findings constitute an incontestable tribute to the scientific significance and medical impact of the still nascent field of substitutive medicine. At the same time, the enormous magnitude of resources dedicated to organ replacement raises several issues related to overall cost effectiveness of current modalities and raises challenges and opportunities for future technical developments.
Assuntos
Transplante de Órgãos , Artroplastia de Substituição/economia , Procedimentos Cirúrgicos Cardíacos/economia , Análise Custo-Benefício , Humanos , Transplante de Órgãos/economia , Diálise Renal/economiaRESUMO
The existing system of organ procurement has failed in its mission of providing an adequate number of organs for transplantation. The organ shortfall results in diminished life expectancy and quality of life for dialysis patients and in increased mortality for patients with end-stage cardiac disease and liver failure who are unable to obtain transplants. Oft-repeated arguments against sale of human organs do not stand up to careful examination, and seem anachronistic in the context of widespread current acceptance of financial incentives for tissue donation in analogous fields, such as reproductive medicine. This essay advocates the staged introduction of a reward-based system of organ donation, initially for cadaveric harvesting and, possibly, later for living donation. Although imperfect, the proposed approach would represent a significant improvement over the status quo.
Assuntos
Marketing de Serviços de Saúde/economia , Doadores de Tecidos , Obtenção de Tecidos e Órgãos/economia , Obtenção de Tecidos e Órgãos/tendências , Europa (Continente) , Humanos , Marketing de Serviços de Saúde/legislação & jurisprudência , Obtenção de Tecidos e Órgãos/legislação & jurisprudência , Estados UnidosRESUMO
Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis. Significant changes in extracorporeal membranes have occurred over the past five decades in which hemodialysis (HD) has been available as a therapy for both acute renal failure (ARF) and end-stage renal disease (ESRD). For cellulosic membranes, these changes have included a reduction in thickness, hydroxyl group substitution, and an increase in pore size. These modifications have resulted in enhanced efficiency of small solute removal, a broader spectrum of overall solute removal, and an attenuation of complement activation in comparison to the thick, unsubstituted cellulosic membranes of low permeability used in the early days of HD therapy. Synthetic membranes, originally developed specifically for use in high-flux HD and hemofiltration, have also evolved during this same time period. In fact, the initially clear distinction between low-flux regenerated cellulosic and high-flux synthetic membranes has become blurred, as membrane formulators have developed products designed to appeal to enthusiasts for both membrane formats. The purpose of this review is to characterize both the solute removal and biocompatibility characteristics of dialysis membranes according to their composition (that is, polymeric makeup) and structure. In this regard, the manner in which membrane biocompatibility interacts with flux is highlighted.
Assuntos
Falência Renal Crônica/terapia , Membranas Artificiais , Diálise Renal/instrumentação , Diálise Renal/tendências , Materiais Biocompatíveis , Soluções para Hemodiálise , HumanosAssuntos
Transplante de Células/métodos , Membranas Artificiais , Terapêutica/métodos , Analgesia , Analgésicos/administração & dosagem , Animais , Órgãos Artificiais , Biotecnologia , Divisão Celular , Células/metabolismo , Diabetes Mellitus/terapia , Terapia Genética , Rejeição de Enxerto/prevenção & controle , Humanos , Falência Hepática/terapia , Transplante HeterólogoRESUMO
The contemporary scope of worldwide tissue engineering research and development was estimated by totaling the relevant annual spending and other economic parameters of firms involved the field. Operating expenses allocated to tissue engineering in 1997 exceed $450 million and fund the activities of nearly 2,500 scientists and support personnel. Growth rate is 22.5% per annum. Most activity is centered in the United States. Government spending in this field represents <10% of the total. The aggregate capital value of start-ups that have gone public was approximately $1.7 billion as of January 1, 1998; total capital value of all firms and business units in the field was estimated to be roughly $3.5 billion. The level of investment and valuation represents a remarkable act of faith in the future of a technology yet to produce its first significant revenue-generating product.
Assuntos
Engenharia Biomédica/economia , Órgãos Artificiais/economia , Engenharia Biomédica/organização & administração , Bioprótese/economia , Economia/estatística & dados numéricos , Financiamento Governamental/estatística & dados numéricos , Organização do Financiamento/estatística & dados numéricos , Humanos , Investimentos em Saúde/estatística & dados numéricos , Apoio à Pesquisa como Assunto , Estados Unidos , Recursos HumanosAssuntos
Falência Renal Crônica/mortalidade , Diálise Renal/métodos , Convecção , Difusão , Feminino , Hemofiltração/métodos , Hemofiltração/estatística & dados numéricos , Humanos , Hipertensão/etiologia , Hipertensão/terapia , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Masculino , Diálise Peritoneal Ambulatorial Contínua/métodos , Diálise Peritoneal Ambulatorial Contínua/estatística & dados numéricos , Diálise Renal/estatística & dados numéricos , Estudos Retrospectivos , Taxa de Sobrevida , Ureia/metabolismoRESUMO
BACKGROUND: Chromaffin cells from the adrenal gland secrete a mixture of compounds that have a strong analgesic effect, especially when administered intrathecally. Many studies in animal models have shown that discordant xenogeneic cell isolates, including chromaffin cells, can survive and have biologic effects when transplanted within a semipermeable membrane capsule. METHODS: To evaluate the clinical potential of encapsulated cell therapy, a human-scale implant containing bovine chromaffin cells was developed, characterized, and implanted in the subarachnoid space of seven patients with severe chronic pain not satisfactorily managed with conventional therapies. Patients received no pharmacologic immunosuppression. Cell devices were implanted during minimally invasive surgery, and device design allowed retrieval. All devices were recovered after implant periods of 41 to 176 days. RESULTS: Postexplant histologic analysis, immunostaining, and secretory function all confirmed survival and biochemical function of the encapsulated cells. Reductions in morphine intake and improvement in pain ratings were observed in several patients. CONCLUSIONS: This study represents the first successful trial of encapsulated xenogeneic cells in humans. The preliminary findings of pain reduction warrant the initiation of a randomized, double-blind phase II study to evaluate the potential efficacy of the procedure.
Assuntos
Células Cromafins/transplante , Implantes de Medicamento , Cuidados Paliativos/métodos , Adulto , Idoso , Animais , Bovinos , Doença Crônica , Sistemas de Liberação de Medicamentos/instrumentação , Feminino , Humanos , Masculino , Membranas Artificiais , Pessoa de Meia-Idade , Transplante HeterólogoRESUMO
Immediately after the availability of highly permeable membranes in 1979, membrane plasma separation was introduced as a mode of extracorporeal blood purification by the nephrology group at Klinikum Grosshadern of the Ludwig Maximilians University of Munich (F.R.G.). The new therapy was applied primarily in the management of immunologically mediated renal and extrarenal disorders as well as in paraproteinemias. We also have witnessed a widespread application of this extracorporeal treatment as a last resort in otherwise refractory clinical conditions. Over the years, the group at Grosshadern has contributed to the development, as well as to the laboratory and clinical testing, of new plasma separation membranes, simplified plasmapheresis formats (e.g., spontaneous membrane plasma separation), and several plasma fractionation procedures (e.g., cascade filtration, adsorption). Whenever indicated and possible, plasma fractionation procedures, rather than unselective plasma exchange, are performed in an appropriate clinical situation.
Assuntos
Plasmaferese , Fracionamento Químico , Feminino , Alemanha , Glomerulonefrite/terapia , Rejeição de Enxerto/terapia , Síndrome Hemolítico-Urêmica , Humanos , Estudos Longitudinais , Lúpus Eritematoso Sistêmico/terapia , Masculino , Membranas Artificiais , Miastenia Gravis/terapia , Paraproteinemias/terapia , Polirradiculoneuropatia/terapia , Púrpura Trombocitopênica Trombótica/terapia , Ensaios Clínicos Controlados Aleatórios como Assunto , Diálise RenalRESUMO
The gene therapy approach presented in this protocol employs a polymer encapsulated, xenogenic, transfected cell line to release human ciliary neurotrophic factor (hCNTF) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A tethered device, containing around 10(6) genetically modified cells surrounded by a semipermeable membrane, is implanted intrathecally; it provides for slow continuous release of hCNTF at a rate of 0.25 to 1.0 micrograms/24 hours. The semipermeable membrane prevents immunologic rejection of the cells and interposes a physical, virally impermeable barrier between cells and host. Moreover, the device and the cells it contains may be retrieved in the event of side effects. A vector containing the human CNTF gene was transfected into a line of baby hamster kidney cells (BHK) with calcium phosphate using a dihydrofolate reductase-based selection vector with a SV40 promoter and contains a HSV-tk killer gene. hCNTF is a potent neurotrophic factor which may have utility for the treatment of ALS. Systemic delivery of hCNTF in humans has been frustrated by peripheral side effects, the molecule's short half life, and its inability to cross the blood-brain barrier. The gene therapy approach described in this protocol is expected to mitigate such difficulties by local intrathecal delivery of a known quantity of continuously-synthesized hCNTF from a retrievable implant.
Assuntos
Esclerose Lateral Amiotrófica/terapia , Terapia Genética/métodos , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/uso terapêutico , Próteses e Implantes , Animais , Cápsulas/química , Cápsulas/uso terapêutico , Linhagem Celular , Transplante de Células/métodos , Células Cultivadas , Fator Neurotrófico Ciliar , Protocolos Clínicos , Cricetinae , Ganciclovir/farmacologia , Vetores Genéticos/genética , Vetores Genéticos/farmacologia , Vetores Genéticos/toxicidade , Humanos , Rim/citologia , Proteínas do Tecido Nervoso/efeitos adversos , Polímeros/química , Polímeros/uso terapêutico , Primatas , Ratos , Ovinos , Simplexvirus/enzimologia , Simplexvirus/genética , Timidina Quinase/genética , TransfecçãoRESUMO
This study relates to the diffusive transport characterization of hollow fibre membranes used in implantable bio-hybrid organs and other immunoisolatory devices. Techniques were developed to accurately determine the mass transfer coefficients for diffusing species in the 10(2)-10(5) MW range, validated and then used to study one membrane type known to effectively immunoisolate both allografts and xenografts in vivo. Low-molecular-weight diffusing markers included glucose, vitamin B12 and cytochrome C; higher-molecular-weight molecules were bovine serum albumin, immunoglobulin G, apoferritin and a range of fluorescein-tagged dextrans. Overall and fractional mass transfer coefficients through the hollow fibres were determined using a resistance-in-series model for transport. A flowing dialysis-type apparatus was used for the small-molecular-weight diffusants, whereas a static diffusion chamber was used for large-molecular-weight markers. For diffusion measurements of small-molecular-weight solutes, convective artefacts were minimized and the effect of boundary layers on both sides of the membrane were accounted for in the model. In measuring diffusion coefficients of large-molecular-weight species, boundary layer effects were shown to be negligible. Results showed that for small-molecular-weight species (< 13,000 MW) the diffusion coefficient in the membrane was reduced relative to diffusion in water by two to four times. The diffusion rate of large-molecular-weight species was hindered by several thousand-fold over their rate of diffusion in water.